As more patients come forward with questions about the potential link between dupilumab (Dupixent®) and certain types of cancer, it’s important to separate facts from speculation. Our team at Morris James is actively investigating claims that Dupixent may increase the risk of cutaneous T-cell lymphoma (CTCL) and other serious conditions….
By: Morris James LLP
By: Morris James LLP